Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial
Cynthia L Comella,Joseph Jankovic,Robert A Hauser,Atul T Patel,Marta D Banach,Edvard Ehler,Domenico Vitarella,Roman G Rubio,Todd M Gross,ASPEN-1 Study Group,Philipp Albrecht,Richard Barbano,Norman Bettle,Sylvia Bösch,Francoise Bouhour,James Boyd,Giovanni Castelnovo,Pratap Chand,Christine Cooper,Susan Criswell,Khashayar Dashtipour,Andres Deik,Aaron Ellenbogen,Virgilio Evidente,Danielle Feigenbaum,Susan Fox,Karen Frei,Jeffrey Gitt,John Goudreau,Behzad Habibi,Timothy Harrower,Bernhard Haslinger,Peter Hedera,Daragh Heitzman,Neal Hermanowicz,Jorge Hernandez Vara,David Isaacs,Stuart Isaacson,Robert Jech,Hyder Jinnah,Christopher Kobylecki,Katja Kollewe,Aikaterini Kompoliti,Dariusz Koziorowski,Alexandre Kreisler,Rajeev Kumar,Andreas Kupsch,Mark LeDoux,Peter LeWitt,Ebba Lohmann,Lydia Lopez Manzanares,Irene Malaty,Janice Massey,Peter Mcallister,Peter Moore,Elena Moro,William Ondo,Javier Pagonabarraga Mora,Sebastian Paus,Elizabeth Peckham,Rekha Pillai,Monika Rudzinska,Harvey Schwartz,Carlos Singer,Jaroslaw Slawek,Thomas Sycha,Dariusz Szabela,Jessica Tate,Nicklesh Thakur,Diego Torres,Jose Maria Trejo,Daniel Truong,Winona Tse,Andrzej Tutaj,Alberto Vasquez,Oldrich Vysata,Ivana Woznicova,Sharon Yegiaian
DOI: https://doi.org/10.1212/WNL.0000000000208091
IF: 9.9
2024-02-27
Neurology
Abstract:Background and objectives: ASPEN-1 was a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, duration of response, and safety of 2 doses of DaxibotulinumtoxinA for Injection (DAXI), a novel botulinum toxin type A formulation in participants with cervical dystonia (CD). Methods: Adults (aged 18-80 years) with moderate-to-severe CD (Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] total score ≥20) were enrolled at 60 sites across 9 countries in Europe and North America. Participants were randomized (3:3:1) to single-dose intramuscular DAXI 125U, 250U, or placebo and followed for up to 36 weeks after injection. The primary end point was change from baseline in TWSTRS total score averaged across weeks 4 and 6. Key secondary end points included duration of effect, Clinical and Patient Global Impression of Change (CGIC, PGIC), TWSTRS subscale scores, and safety. Multiplicity-adjusted intent-to-treat hypothesis tests with multiple imputation were performed using ANCOVA and Cochran-Mantel-Haenszel analyses. Results: Of 444 individuals screened, 301 were randomized to DAXI 125U (n = 125) or 250U (n = 130) or placebo (n = 46). DAXI 125U and 250U significantly improved the mean TWSTRS total score vs placebo (least squares mean [standard error] difference vs placebo: DAXI 125U, -8.5 [1.93], p < 0.0001; DAXI 250U, -6.6 [1.92], p = 0.0006). The median duration of effect (time from treatment until loss of ≥80% of the peak improvement in average TWSTRS total score achieved at weeks 4 and 6) was 24.0 (95% confidence interval 20.3-29.1) weeks with DAXI 125U and 20.3 (16.7-24.0) weeks with DAXI 250U. Significant improvements were also observed with DAXI in CGIC and PGIC responder rates and TWSTRS subscales. Treatment-related treatment-emergent adverse events (TEAEs) were reported by 29.6% of participants with DAXI 125U, 23.8% with DAXI 250U, and 17.4% with placebo, with injection site pain being the most common overall. The most frequently reported treatment-related TEAEs of interest in DAXI 125U, DAXI 250U, and placebo, respectively, were muscular weakness (4.8%, 2.3%, 0%), musculoskeletal pain (2.4%, 3.1%, 0%), and dysphagia (1.6%, 3.8%, 0%). Discussion: This study demonstrated that DAXI, at doses of 125U and 250U, is an effective, safe, long-acting, and well-tolerated treatment for CD. Trial registration information: ClinicalTrials.gov identifier (NCT03608397, submitted July 11, 2018) and EU Clinical Trials Register (ClinicalTrialsRegister.eu EudraCT identifier 2018-000446-19, submitted September 13, 2018). First participant enrolled on June 11, 2018. Trial registration was performed in accordance with the Food and Drug Administration Amendments Act (FDAAA 801), which stipulates that the responsible party register an applicable clinical trial not later than 21 calendar days after enrolling the first human participant (42 CFR 11.24). Classification of evidence: This study provides Class I evidence that in adults with moderate-to-severe idiopathic cervical dystonia, DAXI reduces dystonia more effectively than placebo.